Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001542431 | SCV001761133 | uncertain significance | Hyper-IgE recurrent infection syndrome 4, autosomal recessive | 2020-07-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002032532 | SCV002216261 | uncertain significance | not provided | 2025-02-03 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 816 of the IL6ST protein (p.Lys816Arg). This variant is present in population databases (rs765498089, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with IL6ST-related conditions. ClinVar contains an entry for this variant (Variation ID: 1184414). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004927712 | SCV005602839 | uncertain significance | not specified | 2024-11-24 | criteria provided, single submitter | clinical testing | The c.2447A>G (p.K816R) alteration is located in exon 17 (coding exon 15) of the IL6ST gene. This alteration results from a A to G substitution at nucleotide position 2447, causing the lysine (K) at amino acid position 816 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |